<p>Kura Oncology, Inc.（纳斯达克：KURA - 获取免费报告）内部人士 Brian Powl 于 1 月 27 日（星期二）出售了 6,414 股公司的股票。该股票的平均售价为 8.46 美元，总价值为 54,262.44 美元。交易完成后，该内部人士直接持有 183,275 股公司的股票，估值约为 1,550,506.50 美元。此次交易使其持股减少了 3.38%。该出售在向证券交易委员会的备案中披露，相关信息可通过 SEC 网站获取。</p>
<p>获取 <strong>Kura Oncology</strong> 的提醒：</p>
<h2>Kura Oncology 股价下跌 1.2%</h2>
<ul>
<li>Kintara Therapeutics 是隐藏的宝石吗？</li>
</ul>
<p>KURA 周三开盘价为 8.47 美元。该公司的债务与股本比率为 0.02，流动比率为 5.12，速动比率为 5.12。Kura Oncology, Inc.的 52 周最低价为 5.41 美元，52 周最高价为 12.49 美元。该公司的 50 日移动平均价格为 10.33 美元，200 日移动平均价格为 9.05 美元。该公司的市值为 7.3706 亿美元，市盈率为-3.42，贝塔值为 0.25。</p>
<p>Kura Oncology（纳斯达克：KURA - 获取免费报告）最近于 11 月 4 日（星期二）发布了季度财报。该公司报告每股收益为（0.85 美元），低于市场共识预期的（0.57 美元）0.28 美元。该季度的营业收入为 2075 万美元，而市场共识预期为 1748 万美元。Kura Oncology 的股本回报率为-65.42%，净利润率为-208.48%。研究分析师预测，Kura Oncology, Inc.在当前年度将发布-2.44 美元的每股收益。</p>
<h2>对 Kura Oncology 的对冲基金看法</h2>
<p>机构投资者最近对该股票的持仓进行了调整。EverSource Wealth Advisors LLC 在第三季度将其在 Kura Oncology 的持仓增加了 392.8%。EverSource Wealth Advisors LLC 现在持有 3854 股公司的股票，价值 34000 美元，此前在上个季度又购买了 3072 股。PNC Financial Services Group Inc.在第三季度将其在 Kura Oncology 的持仓增加了 127.2%。PNC Financial Services Group Inc.现在持有 6732 股公司的股票，价值 60000 美元，此前在此期间又收购了 3769 股。Merit Financial Group LLC 在第三季度购买了 Kura Oncology 的新股份，价值约 89000 美元。Jain Global LLC 在第三季度收购了 Kura Oncology 的新持仓，价值约 91000 美元。最后，Lazard Asset Management LLC 在第三季度将其在 Kura Oncology 的持仓增加了 222.3%。Lazard Asset Management LLC 现在持有 10423 股公司的股票，价值 92000 美元，此前在上个季度又购买了 7189 股。</p>
<h2>Kura Oncology 关键新闻</h2>
<p>以下是本周影响 Kura Oncology 的关键新闻：</p>
<ul>
<li>积极情绪：大型机构持有者正在增加在 KURA 的持仓（先锋集团、EcoR1 Capital、Jacobs Levy、Geode、Qube Research），这表明持续的机构信心可能为近期的抛售提供支持。MarketBeat KURA 资料</li>
<li>中性情绪：分析师的覆盖意见不一：几家公司维持买入/跑赢大盘评级，并设定高目标（共识目标约为 28 美元），而其他公司则最近下调或重申卖出观点——这种分歧可能会维持波动，但如果临床/新闻催化剂到来，也会留下上涨空间。分析师笔记</li>
<li>消极情绪：Teresa Brophy Bair（内部人士）以平均 8.46 美元出售了 11208 股（收益约 94,820 美元）；出售后持股 226,931 股（减少约 4.71%）。这位大型董事/高管的出售可能对情绪造成压力。SEC 备案</li>
<li>消极情绪：Mollie Leoni（内部人士）以 8.46 美元出售了 8180 股（收益约 69,203 美元）；出售后持股 267,274 股（减少约 2.97%）。SEC 备案</li>
<li>消极情绪：Thomas James Doyle（高级副总裁）以 8.46 美元出售了 7142 股（收益约 60,421 美元）；出售后持股 145,167 股（减少约 4.69%）。SEC 备案</li>
<li>消极情绪：Kathleen Ford（首席运营官）以 8.46 美元出售了 1813 股（收益约 15,338 美元）；出售后持股 153,560 股（减少约 1.17%）。SEC 备案</li>
<li>消极情绪：Francis Burrows（内部人士）以 8.46 美元出售了 1311 股（收益约 11,091 美元）；出售后持股 32,424 股（减少约 3.89%）。这与 Burrows 在 12 月的先前出售相呼应，表明持续的投资组合削减，而非一次性行为。SEC 备案</li>
</ul>
<h2>分析师评级变动</h2>
<p>多家研究公司对 KURA 进行了评估。JMP Securities 在 10 月 20 日的研究报告中重新发布了 “市场跑赢” 评级，并设定了 24.00 美元的目标价。巴克莱在 11 月 24 日的研究报告中重申了 “增持” 评级，并将 Kura Oncology 的目标价从 11.00 美元上调至 28.00 美元。Zacks Research 在 1 月 20 日的报告中将 Kura Oncology 的评级从 “持有” 下调至 “强烈卖出”。瑞银集团在 11 月 14 日的报告中将 Kura Oncology 的目标价从 14.00 美元上调至 16.00 美元，并给予该股票 “买入” 评级。最后，Leerink Partners 在 1 月 13 日的研究报告中设定了 Kura Oncology 的目标价为 20.00 美元，并给予该股票 “跑赢大盘” 评级。九位投资分析师对该股票给予了买入评级，两位给予了持有评级，两位给予了卖出评级。根据 MarketBeat 的数据，该股票目前的共识评级为 “适度买入”，共识目标价为 28.00 美元。</p>
<p><strong>查看我们关于 Kura Oncology 的最新研究报告</strong></p>
<h2>Kura Oncology 公司简介</h2>
<p>（获取免费报告）</p>
<p>Kura Oncology, Inc NASDAQ: KURA 是一家临床阶段的生物制药公司，专注于靶向肿瘤治疗的发现和开发。公司总部位于加利福尼亚州拉荷亚，利用分子生物学和精准医学的专业知识，识别癌症生长的关键驱动因素，并设计小分子抑制剂以阻断这些通路。Kura 的研究平台将基因组洞察与药物化学相结合，以推进针对固体肿瘤和血液恶性肿瘤中经过良好验证的靶点的候选药物。</p>
<p>公司的主要临床候选药物 tipifarnib 是一种法尼基转移酶抑制剂，正在评估用于治疗 HRAS 突变的头颈部鳞状细胞癌和各种非小细胞肺癌。</p>
<h2>另见</h2>
<ul>
<li>五只我们认为比 Kura Oncology 更好的股票</li>
<li>美国的下一个权力举动从地下开始</li>
<li>你的签名缺失 - 在为时已晚之前采取行动</li>
<li>新法律：国会批准数字美元的设立？</li>
<li>1933 年的退款：特朗普的重置可能创造即时财富</li>
<li>BSEM：目标价 25.50 美元，纳斯达克在望！</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/InsiderTradesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9S1VSQQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/InsiderTradesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9S1VSQQ"/></p>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或评论发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1000 美元在 Kura Oncology 吗？</h2>
<p>在考虑 Kura Oncology 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄建议客户在更广泛的市场注意到之前购买的股票……而 Kura Oncology 并不在名单上。</p>
<p>虽然 Kura Oncology 目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

医药突破 ETF - ALPS

动态生物技术与基因组 ETF - Invesco

纽交所高增长板生物技术指数 ETF - First Trust

纳斯达克生物科技指数 ETF - iShares Nasdaq

IBBQ

基因改革 ETF - ARK

生物科技 ETF - VanEck Vectors

2 倍做多纳斯达克生物技术 ETF - ProShares

标普生物技术 ETF - SPDR

KURA

<p>Kura Oncology 的内部人士 Brian Powl 以每股 8.46 美元的价格出售了 6,414 股，总计 54,262.44 美元，减少了 3.38% 的持股比例。出售后，他持有 183,275 股，价值约 155 万美元。此次出售已向美国证券交易委员会（SEC）披露。Kura 的股票开盘价为 8.47 美元，市值为 7.3706 亿美元，市盈率为 -3.42。近期的内部人士出售引发了市场担忧，影响了市场情绪，尽管一些机构投资者增加了他们的持仓。分析师的评级不一，普遍目标价约为 28 美元</p>

<p>Kura Oncology, Inc. (NASDAQ:KURA - Get Free Report) insider Brian Powl sold 6,414 shares of the company's stock in a transaction dated Tuesday, January 27th. The stock was sold at an average price of $8.46, for a total value of $54,262.44. Following the completion of the transaction, the insider directly owned 183,275 shares of the company's stock, valued at approximately $1,550,506.50. The trade was a 3.38% decrease in their position. The sale was disclosed in a filing with the Securities &amp; Exchange Commission, which is accessible through the SEC website.</p>
<div class="lb-trans"><p>Kura Oncology, Inc.（纳斯达克：KURA - 获取免费报告）内部人士 Brian Powl 于 1 月 27 日（星期二）出售了 6,414 股公司的股票。该股票的平均售价为 8.46 美元，总价值为 54,262.44 美元。交易完成后，该内部人士直接持有 183,275 股公司的股票，估值约为 1,550,506.50 美元。此次交易使其持股减少了 3.38%。该出售在向证券交易委员会的备案中披露，相关信息可通过 SEC 网站获取。</p>
</div><p>Get <strong>Kura Oncology</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>Kura Oncology</strong> 的提醒：</p>
</div><h2>Kura Oncology Trading Down 1.2%</h2>
<div class="lb-trans"><h2>Kura Oncology 股价下跌 1.2%</h2>
</div><ul>
<li>Is Kintara Therapeutics A Hidden Gem?</li>
</ul>
<div class="lb-trans"><ul>
<li>Kintara Therapeutics 是隐藏的宝石吗？</li>
</ul>
</div><p>KURA opened at $8.47 on Wednesday. The company has a debt-to-equity ratio of 0.02, a current ratio of 5.12 and a quick ratio of 5.12. Kura Oncology, Inc. has a fifty-two week low of $5.41 and a fifty-two week high of $12.49. The company's 50 day moving average price is $10.33 and its two-hundred day moving average price is $9.05. The firm has a market capitalization of $737.06 million, a price-to-earnings ratio of -3.42 and a beta of 0.25.</p>
<div class="lb-trans"><p>KURA 周三开盘价为 8.47 美元。该公司的债务与股本比率为 0.02，流动比率为 5.12，速动比率为 5.12。Kura Oncology, Inc.的 52 周最低价为 5.41 美元，52 周最高价为 12.49 美元。该公司的 50 日移动平均价格为 10.33 美元，200 日移动平均价格为 9.05 美元。该公司的市值为 7.3706 亿美元，市盈率为-3.42，贝塔值为 0.25。</p>
</div><p>Kura Oncology (NASDAQ:KURA - Get Free Report) last issued its quarterly earnings data on Tuesday, November 4th. The company reported ($0.85) earnings per share for the quarter, missing the consensus estimate of ($0.57) by ($0.28). The business had revenue of $20.75 million during the quarter, compared to the consensus estimate of $17.48 million. Kura Oncology had a negative return on equity of 65.42% and a negative net margin of 208.48%. As a group, research analysts predict that Kura Oncology, Inc. will post -2.44 earnings per share for the current year.</p>
<div class="lb-trans"><p>Kura Oncology（纳斯达克：KURA - 获取免费报告）最近于 11 月 4 日（星期二）发布了季度财报。该公司报告每股收益为（0.85 美元），低于市场共识预期的（0.57 美元）0.28 美元。该季度的营业收入为 2075 万美元，而市场共识预期为 1748 万美元。Kura Oncology 的股本回报率为-65.42%，净利润率为-208.48%。研究分析师预测，Kura Oncology, Inc.在当前年度将发布-2.44 美元的每股收益。</p>
</div><h2>Hedge Funds Weigh In On Kura Oncology</h2>
<div class="lb-trans"><h2>对 Kura Oncology 的对冲基金看法</h2>
</div><p>Institutional investors have recently made changes to their positions in the stock. EverSource Wealth Advisors LLC increased its position in Kura Oncology by 392.8% in the 3rd quarter. EverSource Wealth Advisors LLC now owns 3,854 shares of the company's stock valued at $34,000 after buying an additional 3,072 shares in the last quarter. PNC Financial Services Group Inc. grew its stake in Kura Oncology by 127.2% in the third quarter. PNC Financial Services Group Inc. now owns 6,732 shares of the company's stock valued at $60,000 after acquiring an additional 3,769 shares during the period. Merit Financial Group LLC bought a new stake in shares of Kura Oncology during the third quarter valued at approximately $89,000. Jain Global LLC acquired a new position in shares of Kura Oncology during the third quarter worth approximately $91,000. Finally, Lazard Asset Management LLC lifted its holdings in shares of Kura Oncology by 222.3% in the 3rd quarter. Lazard Asset Management LLC now owns 10,423 shares of the company's stock worth $92,000 after purchasing an additional 7,189 shares in the last quarter.</p>
<div class="lb-trans"><p>机构投资者最近对该股票的持仓进行了调整。EverSource Wealth Advisors LLC 在第三季度将其在 Kura Oncology 的持仓增加了 392.8%。EverSource Wealth Advisors LLC 现在持有 3854 股公司的股票，价值 34000 美元，此前在上个季度又购买了 3072 股。PNC Financial Services Group Inc.在第三季度将其在 Kura Oncology 的持仓增加了 127.2%。PNC Financial Services Group Inc.现在持有 6732 股公司的股票，价值 60000 美元，此前在此期间又收购了 3769 股。Merit Financial Group LLC 在第三季度购买了 Kura Oncology 的新股份，价值约 89000 美元。Jain Global LLC 在第三季度收购了 Kura Oncology 的新持仓，价值约 91000 美元。最后，Lazard Asset Management LLC 在第三季度将其在 Kura Oncology 的持仓增加了 222.3%。Lazard Asset Management LLC 现在持有 10423 股公司的股票，价值 92000 美元，此前在上个季度又购买了 7189 股。</p>
</div><h2>Key Kura Oncology News</h2>
<div class="lb-trans"><h2>Kura Oncology 关键新闻</h2>
</div><p>Here are the key news stories impacting Kura Oncology this week:</p>
<div class="lb-trans"><p>以下是本周影响 Kura Oncology 的关键新闻：</p>
</div><ul>
<li>Positive Sentiment: Large institutional holders have been increasing positions in KURA (Vanguard, EcoR1 Capital, Jacobs Levy, Geode, Qube Research), signaling continued institutional conviction that could provide support under recent selling. MarketBeat KURA profile</li>
<li>Neutral Sentiment: Analyst coverage is mixed: several firms maintain buy/outperform ratings with high targets (consensus target ~ $28), while others recently downgraded or reiterated sell views — a split that can sustain volatility but also leaves upside if clinical/news catalysts arrive. Analyst notes</li>
<li>Negative Sentiment: Teresa Brophy Bair (insider) sold 11,208 shares at an average $8.46 (proceeds ~$94,820); post-sale holdings 226,931 shares (~4.71% reduction). This large director/officer sale is likely weighing on sentiment. SEC filing</li>
<li>Negative Sentiment: Mollie Leoni (insider) sold 8,180 shares at $8.46 (proceeds ~$69,203); post-sale holdings 267,274 shares (~2.97% reduction). SEC filing</li>
<li>Negative Sentiment: Thomas James Doyle (SVP) sold 7,142 shares at $8.46 (proceeds ~$60,421); post-sale holdings 145,167 shares (~4.69% reduction). SEC filing</li>
<li>Negative Sentiment: Kathleen Ford (COO) sold 1,813 shares at $8.46 (proceeds ~$15,338); post-sale holdings 153,560 shares (~1.17% reduction). SEC filing</li>
<li>Negative Sentiment: Francis Burrows (insider) sold 1,311 shares at $8.46 (proceeds ~$11,091); post-sale holdings 32,424 shares (~3.89% reduction). This follows prior Burrows sales in December, suggesting ongoing portfolio trimming rather than a one-off. SEC filing</li>
</ul>
<div class="lb-trans"><ul>
<li>积极情绪：大型机构持有者正在增加在 KURA 的持仓（先锋集团、EcoR1 Capital、Jacobs Levy、Geode、Qube Research），这表明持续的机构信心可能为近期的抛售提供支持。MarketBeat KURA 资料</li>
<li>中性情绪：分析师的覆盖意见不一：几家公司维持买入/跑赢大盘评级，并设定高目标（共识目标约为 28 美元），而其他公司则最近下调或重申卖出观点——这种分歧可能会维持波动，但如果临床/新闻催化剂到来，也会留下上涨空间。分析师笔记</li>
<li>消极情绪：Teresa Brophy Bair（内部人士）以平均 8.46 美元出售了 11208 股（收益约 94,820 美元）；出售后持股 226,931 股（减少约 4.71%）。这位大型董事/高管的出售可能对情绪造成压力。SEC 备案</li>
<li>消极情绪：Mollie Leoni（内部人士）以 8.46 美元出售了 8180 股（收益约 69,203 美元）；出售后持股 267,274 股（减少约 2.97%）。SEC 备案</li>
<li>消极情绪：Thomas James Doyle（高级副总裁）以 8.46 美元出售了 7142 股（收益约 60,421 美元）；出售后持股 145,167 股（减少约 4.69%）。SEC 备案</li>
<li>消极情绪：Kathleen Ford（首席运营官）以 8.46 美元出售了 1813 股（收益约 15,338 美元）；出售后持股 153,560 股（减少约 1.17%）。SEC 备案</li>
<li>消极情绪：Francis Burrows（内部人士）以 8.46 美元出售了 1311 股（收益约 11,091 美元）；出售后持股 32,424 股（减少约 3.89%）。这与 Burrows 在 12 月的先前出售相呼应，表明持续的投资组合削减，而非一次性行为。SEC 备案</li>
</ul>
</div><h2>Analyst Ratings Changes</h2>
<div class="lb-trans"><h2>分析师评级变动</h2>
</div><p>A number of research firms have weighed in on KURA. JMP Securities reissued a &#34;market outperform&#34; rating and set a $24.00 target price on shares of Kura Oncology in a research report on Monday, October 20th. Barclays reiterated an &#34;overweight&#34; rating and set a $28.00 price objective (up from $11.00) on shares of Kura Oncology in a research report on Monday, November 24th. Zacks Research lowered shares of Kura Oncology from a &#34;hold&#34; rating to a &#34;strong sell&#34; rating in a report on Tuesday, January 20th. UBS Group increased their price target on Kura Oncology from $14.00 to $16.00 and gave the stock a &#34;buy&#34; rating in a report on Friday, November 14th. Finally, Leerink Partners set a $20.00 price objective on Kura Oncology and gave the stock an &#34;outperform&#34; rating in a research report on Tuesday, January 13th. Nine investment analysts have rated the stock with a Buy rating, two have issued a Hold rating and two have assigned a Sell rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of &#34;Moderate Buy&#34; and a consensus price target of $28.00.</p>
<div class="lb-trans"><p>多家研究公司对 KURA 进行了评估。JMP Securities 在 10 月 20 日的研究报告中重新发布了 “市场跑赢” 评级，并设定了 24.00 美元的目标价。巴克莱在 11 月 24 日的研究报告中重申了 “增持” 评级，并将 Kura Oncology 的目标价从 11.00 美元上调至 28.00 美元。Zacks Research 在 1 月 20 日的报告中将 Kura Oncology 的评级从 “持有” 下调至 “强烈卖出”。瑞银集团在 11 月 14 日的报告中将 Kura Oncology 的目标价从 14.00 美元上调至 16.00 美元，并给予该股票 “买入” 评级。最后，Leerink Partners 在 1 月 13 日的研究报告中设定了 Kura Oncology 的目标价为 20.00 美元，并给予该股票 “跑赢大盘” 评级。九位投资分析师对该股票给予了买入评级，两位给予了持有评级，两位给予了卖出评级。根据 MarketBeat 的数据，该股票目前的共识评级为 “适度买入”，共识目标价为 28.00 美元。</p>
</div><p><strong>View Our Latest Research Report on Kura Oncology</strong></p>
<div class="lb-trans"><p><strong>查看我们关于 Kura Oncology 的最新研究报告</strong></p>
</div><h2>Kura Oncology Company Profile</h2>
<div class="lb-trans"><h2>Kura Oncology 公司简介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>Kura Oncology, Inc NASDAQ: KURA is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted oncology therapies. Headquartered in La Jolla, California, the company leverages expertise in molecular biology and precision medicine to identify key drivers of cancer growth and design small-molecule inhibitors that block those pathways. Kura's research platform integrates genomic insights with medicinal chemistry to advance candidates against well-validated targets in solid tumors and hematologic malignancies.</p>
<div class="lb-trans"><p>Kura Oncology, Inc NASDAQ: KURA 是一家临床阶段的生物制药公司，专注于靶向肿瘤治疗的发现和开发。公司总部位于加利福尼亚州拉荷亚，利用分子生物学和精准医学的专业知识，识别癌症生长的关键驱动因素，并设计小分子抑制剂以阻断这些通路。Kura 的研究平台将基因组洞察与药物化学相结合，以推进针对固体肿瘤和血液恶性肿瘤中经过良好验证的靶点的候选药物。</p>
</div><p>The company's lead clinical candidate, tipifarnib, is a farnesyltransferase inhibitor being evaluated for the treatment of HRAS-mutant head and neck squamous cell carcinoma and various non-small cell lung cancers.</p>
<div class="lb-trans"><p>公司的主要临床候选药物 tipifarnib 是一种法尼基转移酶抑制剂，正在评估用于治疗 HRAS 突变的头颈部鳞状细胞癌和各种非小细胞肺癌。</p>
</div><h2>See Also</h2>
<div class="lb-trans"><h2>另见</h2>
</div><ul>
<li>Five stocks we like better than Kura Oncology</li>
<li>America's Next Power Move Starts Underground</li>
<li>Your Signature Is Missing – Act Before It’s Too Late</li>
<li>NEW LAW: Congress Approves Setup For Digital Dollar?</li>
<li>Refund From 1933: Trump’s Reset May Create Instant Wealth</li>
<li>BSEM: A $25.50 Price Target, and Nasdaq on the Horizon!</li>
</ul>
<div class="lb-trans"><ul>
<li>五只我们认为比 Kura Oncology 更好的股票</li>
<li>美国的下一个权力举动从地下开始</li>
<li>你的签名缺失 - 在为时已晚之前采取行动</li>
<li>新法律：国会批准数字美元的设立？</li>
<li>1933 年的退款：特朗普的重置可能创造即时财富</li>
<li>BSEM：目标价 25.50 美元，纳斯达克在望！</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/InsiderTradesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9S1VSQQ" alt="" original-src="https://www.marketbeat.com/scripts/InsiderTradesChart.ashx?Prefix=NASDAQ&amp;Symbol=KURA"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或评论发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Kura Oncology Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1000 美元在 Kura Oncology 吗？</h2>
</div><p>Before you consider Kura Oncology, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑 Kura Oncology 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Kura Oncology wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄建议客户在更广泛的市场注意到之前购买的股票……而 Kura Oncology 并不在名单上。</p>
</div><p>While Kura Oncology currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Kura Oncology 目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Insider Selling: Kura Oncology (NASDAQ:KURA) Insider Sells 6,414 Shares of Stock

Market Beat

Invesco Nasdaq Biotechnology ETF

Kura Oncology

内幕交易：Kura Oncology（纳斯达克代码：KURA）内部人士出售 6414 股股票